The tuberculin skin test is unreliable in school children BCG-vaccinated in infancy and at low risk of tuberculosis infection

Pediatric Infectious Disease Journal

Volumn 30, Issue 9, 2011, Pages 754-758

  Jacobs, Sandy ^a   Warman, Andrea ^a   Richardson, Ruth ^a   Yacoub, Wadieh ^a   Lau, Angela ^b   Whittaker, Denise ^c   Cockburn, Sandy ^c   Verma, Geetu ^b,c   Boffa, Jody ^b   Tyrrell, Gregory ^d   Kunimoto, Dennis ^b   Manfreda, Jure ^b   Langlois Klassen, Deanne ^b   Long, Richard ^b,c  

^a First Nations and Inuit Health   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ALBERTA HEALTH SERVICES   (Canada)

^d Provincial Laboratory for Public Health   (Canada)

Author keywords

BCG vaccinated; interferon gamma release assays; Latent tuberculosis infection; tuberculin tests

Indexed keywords

BCG VACCINE;

ARTICLE; CHILD; FEMALE; HUMAN; LATENT TUBERCULOSIS INFECTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SCREENING; TUBERCULIN TEST; TUBERCULOSIS; VACCINATION;

EID: 80051927559     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31821b8f54     Document Type: Article

References (36)

1. Public Health Agency of Canada. Tuberculosis in Canada 2008. Ottawa, Ontario, Canada: Minister of Public Works and Government Services Canada; 2010. Available at: http://www.publichealth.gc.ca/tuberculosis.
2. Yip D, Bhargava R, Yao Y, et al. Pediatric tuberculosis in Alberta: Epidemiology and case characteristics (1990-2004). Can J Public Health. 2007;98:276-280.
3. Menzies R, Vissandjee B. Effect of bacille Calmette-Guérin vaccination on tuberculin reactivity. Am Rev Respir Dis. 1992;145:621-625.
4. Farhat M, Greenaway C, Pai M, et al. False positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10:1192-1204. (Pubitemid 44713473)
5. Cook V, Kuramoto L, Noertjojo K, et al. BCG vaccination and the prevalence of latent tuberculosis infection in an Aboriginal population. Int J Tuberc Lung Dis. 2006;10:1347-1353. (Pubitemid 44924588)
6. Reid J, Ward H, Marciniuk D, et al. The effect of neonatal bacille Calmette-Guérin vaccination on purified protein derivative skin test results in Canadian aboriginal children. Chest. 2007;131:1806-1810. (Pubitemid 46981638)
7. Chan PC, Chang LY, Wu YC, et al. Age-specific cut-offs for the tuberculin skin test to detect latent tuberculosis in BCG-vaccinated children. Int J Tuberc Lung Dis. 2008;12:1401-1406.
8. International Union Against Tuberculosis and Lung Disease. Criteria for discontinuation of vaccination programmes using bacilli Calmette-Guérin (BCG) in countries with low prevalence of tuberculosis. Tuberc Lung Dis. 1994;75:179-181.
9. Magnus K, Edwards L. The effect of repeated tuberculin testing on post-vaccination allergy. Lancet. 1955;24:643-644.
10. Guld J, Waaler H, Sundaresan TK, et al. The duration of BCG-induced tuberculin sensitivity in children, and its irrelevance for revaccination. Bull World Health Organ. 1968;39:829-836.
11. Sepulveda R, Burr C, Ferrer X, et al. Booster effect of tuberculin testing in healthy 6-year-old school children vaccinated with bacillus Calmette-Guérin at birth in Santiago, Chile. Pediatr Infect Dis J. 1988;7:578-581.
12. Pabst HF, Godel JC, Spady DW, et al. Prospective trial of timing of bacillus Calmette-Guérin vaccination in Canadian Cree infants. Am Rev Respir Dis. 1989;140:1007-2010.
13. Chun JK, Kim CK, Kim HS, et al. The role of a whole blood interferongamma assay for the detection of latent tuberculosis infection in bacille Calmette-Guérin vaccinated children. Diagn Microbiol Infect Dis. 2008;62: 389-394.
14. Canadian Tuberculosis Committee. Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). Can Comm Dis Rep. 2008;34:1-13.
15. Bergamini BM, Losi M, Vaienti F, et al. Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. Pediatrics. 2009;123:e419-e424.
16. Powell DA. Interferon gamma release assays in the evaluation of children with possible Mycobacterium tuberculosis infection. Pediatr Infect Dis J. 2009;28:676-677.
17. Lighter J, Rigaud M, Eduardo R, et al. Latent tuberculosis diagnosis in children by using the QuantiFERON-TB Gold In-Tube test. Pediatrics. 2009;123:30-37.
18. Haustein T, Ridout DA, Hartley JC, et al. The Likelihood of an indeterminate test result from a whole-blood interferon-release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis J. 2009;28:669-673.
19. Lewinsohn DA, Lobato MN, Jereb JA. Interferon-γ release assays: new diagnostics tests for Mycobacterium tuberculosis infection, and their use in children. Curr Opin Pediatr. 2010;22:71-76.
20. Centers for Disease Control and Prevention. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. Morb Mortal Wkly Rep. 2010;59(RR-5): 1-25.
21. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177-184.
22. Jacobs S, Warman A, Roehrig N, et al. Mycobacterium tuberculosis infection in First Nations preschool children in Alberta: Implications for BCG (bacille Calmette-Guérin) withdrawal. Can J Public Health. 2007;98: 116-120.
23. Milloy JS. A National Crime. The Canadian Government and the Residential School System: 1879-1986. Winnipeg, Manitoba, Canada: The University of Manitoba Press; 1999.
24. Young TK, Mirdad S. Determinants of tuberculin sensitivity in a child population covered by mass BCG vaccination. Tuber Lung Dis. 1992;73: 94-100.
25. Behr MA, Small PM. Has BCG attenuated to impotence? Nature. 1987; 389:133-134.
26. Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 1999;284:1520-1523.
27. van ZyL-Smit RN, Pai M, Peprah K, et al. Within-subject variability and boosting of T-cell interferon-γ responses after tuberculin skin testing. Am J Respir Crit Care Med. 2009;180:49-58.
28. van zyl-Smit RN, Zwerling A, Dheda K, et al. Within subject variability of interferon-γ assay results for tuberculosis and boosting effect of tuberculin skin testing: systematic review. PLoS ONE. 2009;4:e8517.
29. Higuchi K, Kondo S, Wada M, et al. Contact investigation in a primary school using a whole blood interferon-gamma assay. J Infect. 2009;58:352-357.
30. Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. Pediatrics. 2004;114:1175-1201.
31. Brassard P, Steensma C, Cadieux L, et al. Evaluation of a school-based tuberculosis screening program and associate investigation targeting recently immigrated children in a low burden country. Pediatrics. 2006;117: e148-e156. (Pubitemid 46071568)
32. The Canadian Lung Association and the Public Health Agency of Canada. The Canadian Tuberculosis Standards. 6th ed. The Canadian Lung Association and the Public Health Agency of Canada;, 2007. Available at: http://www.publichealth.gc. ca/tuberculosis
33. CDC. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection-United States, 2004-2008. MMWR. 2010;59:224-229.
34. Menzies D, Lewis M, Oxlade O. Costs for tuberculosis care in Canada. Can J Public Health. 2008;99:391-396.
35. Kunimoto D, Der E, Beckon A, et al. Use of the QuantiFERON-TB Gold test to confirm latent tuberculosis infection in a Canadian Tuberculosis Clinic. Int J Tuberc Lung Dis. 2009;13:726-730.
36. Winje BA, Oftung F, Korsvold GE, et al. School based screening for tuberculosis infection in Norway: comparison of positive tuberculin skin test with interferon-gamma release assay. BMC Infect Dis. 2008;8:140. Available at: http://www.biomedcentral.com/1471-2334/8/140.